Claims for Patent: 7,795,017

Summary for Patent: 7,795,017

Title:	DNA expression vectors and methods of use
Abstract:	The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is particularly useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types, thereby reducing the possibility of the targeted virus escaping the immune response. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine vector includes a transcription cassette expressing the same vaccine insert as the primary immunizing vector.
Inventor(s):	Robinson; Harriet L. (Atlanta, GA), Amara; Rama R. (Atlanta, GA), Ross; Ted M. (Aspinall, PA), Bright; Rick A. (Atlanta, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	11/009,063
Patent Claims:	1. A vector comprising: (a) a gene encoding kanamycin resistance; (b) Col E1 replicator; (c) a lambda T0 terminator operably linked to the gene encoding kanamycin resistance; and (d) a eukaryotic transcription cassette comprising a CMV immediately early promoter, a polyadenylation signal sequence, and a nucleic acid sequence encoding: an HIV gag protein; an HIV pol protein fragment lacking the integrase domain and having amino acid changes at Asp185, Trp266, and Glu478; an HIV tat protein; an HIV rev protein; an HIV vpu protein; and an HIV env protein. 2. The vector of claim 1, wherein the HIV proteins are HIV clade B proteins. 3. The vector of claim 2, HIV Glade B proteins are HIV BH10 proteins or HIV ADA proteins. 4. The vector of claim 1, wherein the eukaryotic transcription cassette further comprises intron A of the CMV immediate early promoter. 5. The vector of claim 1, wherein the polyadenylation sequence is the rabbit beta globin polyadenylation sequence. 6. The vector of claim 1, wherein the polyadenylation sequence is the bovine growth hormone polyadenylation sequence. 7. A vector comprising the nucleotide sequence of SEQ ID NO:2. 8. The vector of claim 1, wherein Asp185 is changed to Asn, Trp266 is changed to Thr, and Glu478 is changed to Gln. 9. The vector of claim 1 or 8, wherein the HIV gag protein has amino acid changes at Cys392, Cys395, Cys413 and Cys416. 10. The vector of claim 9, wherein Cys392 is changed to Ser, Cys395 is changed to Ser, Cys413 is changed to Ser and Cys416 is changed to Ser.

Details for Patent 7,795,017

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-03-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-03-02